You are here

Article Text

Article menu
Download PDFPDF
Ovarian Cancer
Erythropoietin Is Detectable in the Ascitic Fluid in Patients With Ovarian Tumors
  1. Vedran Stefanovic, MD, PhD*,†,
  2. Päivi Pakarinen, MD, PhD*,
  3. Henrik Alfthan, PhD‡,
  4. Ulf-Håkan Stenman, MD, PhD‡,
  5. Arto Leminen, MD, PhD*,
  6. Jurate Pociuviene, MD*,
  7. Annika Riska, MD, PhD* and
  8. Mikko Loukovaara, MD, PhD*
  1. *Department of Obstetrics and Gynecology, Helsinki University Central Hospital;
  2. †Institute of Clinical Medicine, Medical Faculty, University of Helsinki; and
  3. ‡Clinical Chemistry, Helsinki University Central Hospital, Helsinki, Finland.
  1. Address correspondence and reprint requests to Vedran Stefanovic, MD, PhD, Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Haartmaninkatu 2, 00290 Helsinki, FINLAND. E-mail: vedran.stefanovic@hus.fi.

Abstract

Background and Objective Erythropoietin (Epo) is a glycoprotein that stimulates proliferation and migration of human endothelial cells and promotes angiogenesis, which are crucial phenomena in cancer biology. The objective of this study was to investigate whether Epo is detectable in the ascitic fluid of patients with ovarian tumors.

Patients and Methods We investigated the presence of Epo in the ascitic fluid of 100 women undergoing laparotomy for an ovarian tumor. Epo concentration was quantitated with an immunochemiluminometric assay.

Results Ten women had a benign tumor, 13 women had a borderline tumor, and 77 women had ovarian cancer. Epo was detected in all ascitic fluid samples, in similar amounts as in corresponding serum samples. Ascitic fluid Epo concentration did not differ between the 3 study groups (P = 0.081), but in multiple comparisons, ascitic fluid Epo was higher in the women with cancer than in the women with a benign tumor (P = 0.006). Ascitic fluid Epo concentration correlated positively with serum Epo (P < 0.0001) and the volume of ascites (P < 0.0001). In regression analyses, serum Epo, volume of ascites, blood hemoglobin, plasma CA125, tumor stage, tumor grade, and the presence of residual tumor after surgery had no significant independent effect on ascitic fluid Epo.

Conclusion Considerable amounts of Epo are present in the ascitic fluid of women with ovarian tumors. The origin of Epo in the ascitic fluid of women with ovarian tumors as well as the clinical relevance of our finding remain to be clarified.

  • Erythropoietin
  • Ascitic fluid
  • Ovarian tumor
  • Ovarian cancer

https://doi.org/10.1097/IGC.0b013e31826fd607

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Vedran Stefanovic and Päivi Pakarinen contributed equally to this work.

    • The authors declare no conflict of interest